London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...

GlaxoSmithKline Pharma is shifting focus to specialty treatments and preventive healthcare, emphasizing adult vaccines and ...

The regulatory clearance for Alembic Pharma's Gujarat facility came without any observations. The USFDA had inspected the ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology ...

Global Heparin Market was valued at US$ 10.76 billion in 2023 and is projected to surpass a valuation of US$ 15.58 billion by 2032 at a CAGR of 4.2% during the forecast period 2024–2032.

Responding to growing pressure, ViiV Healthcare announced steps to widen access to its HIV prevention medicine in low- and ...

Faced with a moribund share sale outlook and emboldened by their growing recognition on the global stage, some Chinese ...

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior ...

GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...

The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving ...

Merck faces a class-action lawsuit over alleged misrepresentation of its mumps vaccine potency, claiming anticompetitive ...